Clayton Financial Group LLC acquired a new stake in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,893 shares of the company's stock, valued at approximately $275,000.
Other large investors also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Mesoblast during the fourth quarter valued at approximately $30,000. Signaturefd LLC raised its stake in Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company's stock valued at $45,000 after acquiring an additional 3,099 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock worth $133,000 after purchasing an additional 1,213 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Mesoblast during the fourth quarter valued at $134,000. Finally, Ballentine Partners LLC bought a new stake in shares of Mesoblast during the fourth quarter valued at about $222,000. Institutional investors own 1.43% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have commented on MESO shares. Jefferies Financial Group downgraded shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. Piper Sandler restated an "overweight" rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a report on Friday. Finally, Cantor Fitzgerald raised shares of Mesoblast to a "strong-buy" rating in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $18.00.
Get Our Latest Report on Mesoblast
Mesoblast Stock Performance
NASDAQ MESO traded up $0.80 on Friday, reaching $19.49. The stock had a trading volume of 335,237 shares, compared to its average volume of 363,955. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. Mesoblast Limited has a 1 year low of $1.75 and a 1 year high of $22.00. The business has a 50 day moving average price of $16.48 and a 200 day moving average price of $11.00.
Mesoblast Company Profile
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
